NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on improving surgical care for neurological disorders, announced that its independent directors approved an equity award under the company's 2021 Inducement Plan on June 24, 2026. The award, which consists of an option to purchase 10,000 shares of common stock, was granted as a material inducement to an individual entering into employment with NeuroOne, in accordance with Nasdaq Listing Rule 5635(c)(4). This rule requires public disclosure of equity awards not made under a stockholder-approved plan, ensuring transparency for investors.
The option has an exercise price of $3.27 per share, equal to the closing price of NeuroOne's common stock on the grant date. It has a ten-year term and vests over four years, with 25% vesting on June 24, 2027, and the remainder vesting in equal quarterly installments thereafter, subject to continued employment and potential acceleration or forfeiture as outlined in the option agreement. The new hire was not a previous employee or director of the company, emphasizing the use of equity incentives to attract external talent.
This inducement grant underscores NeuroOne's strategy to secure key personnel as it advances its product portfolio. The company markets four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System for the brain, and OneRF® Trigeminal Nerve Ablation System. These technologies aim to reduce hospitalizations and surgical procedures, lower costs, and improve patient outcomes by combining diagnostic and therapeutic functions. Additionally, NeuroOne is engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
The announcement is significant for investors as it reflects the company's commitment to building its workforce while adhering to Nasdaq corporate governance standards. By providing this disclosure, NeuroOne maintains compliance with listing requirements, which is crucial for its continued presence on the exchange. For more information about the company and its technologies, visit nmtc1.com.
